Program
Anti-CD19/CD3 Bispecific Antibody MK-1045
Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Follicular · Lymphoma, Non-Hodgkin · Burkitt Lymphoma · Lymphoma, Large B-Cell, Diffuse, led by Merck.
Drug pageAnti-CD19/CD3 Bispecific Antibody MK-1045: every studyAll 8 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 88 open or running | phase 3since Apr 29, 2026 | Oct 7, 2022 | Sep 30, 2028phase 1 · NCT06189391 |
- Named in Merck’s own pipeline as
MK-1045
, phase 2, as of Nov 2, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 7, 2022First study: phase 2 study in Precursor Cell Lymphoblastic Leukemia-LymphomaFirst studyNCT05579132 · 203 planned · China
- Aug 30, 2023Phase 1 study in RecurrenceNCT06189391 · 100 planned · China
- Jan 16, 2026Phase 1 study in Lupus Erythematosus, SystemicNCT07363590 · 21 planned · Australia, Belgium, China and more
- Apr 3, 2026Phase 2 study in Lymphoma, Non-HodgkinNCT07519772 · 280 planned · United States, Argentina, Australia and more
- Apr 29, 2026Phase 3 study in Burkitt LymphomaPhase 3 reachedNCT07570173 · 340 planned · Canada, Denmark, France and more
- Jun 4, 2026Phase 3 study in Lymphoma, FollicularNCT07634471 · 960 planned · United States, Argentina, Australia and more
- Jul 13, 2026Phase 2 study in Leukemia, B-CellNCT07709000 · 60 planned · Colombia, Israel, Spain
- Oct 28, 2026Phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT07917754 · 470 planned
Ahead
- Sep 30, 2028Primary completion: phase 1 study in RecurrenceNCT06189391
- Dec 31, 2028Primary completion: phase 2 study in Precursor Cell Lymphoblastic Leukemia-LymphomaNCT05579132
- Jul 16, 2029Primary completion: phase 1 study in Lupus Erythematosus, SystemicNCT07363590
- Jul 1, 2030Primary completion: phase 2 study in Lymphoma, Non-HodgkinNCT07519772
TargetBeta
“An immunoglobulin G4 (IgG4) bispecific antibody and a T-cell engager targeting both the tumor-associated antigen (TAA) CD19, and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19/CD3 bispecific antibody MK-1045 binds to …”NCIt, read by Claude
“An immunoglobulin G4 (IgG4) bispecific antibody and a T-cell engager targeting both the tumor-associated antigen (TAA) CD19, and the T-cell surface antigen CD3, ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| blinatumomabrule | Amgen | phase 4 | 29 |
| surovatamig | AstraZeneca | phase 3 | 10 |
| YK012rule | excyte-biopharma-ltd | phase 2 | 5 |
| GSK5926371 | GlaxoSmithKline | phase 2 | 2 |
| Anti-CD19/CD3 T-cell Engaging Bispecific Antibody CLN-978rule | cullinan-therapeutics-inc | phase 1 | 4 |
| Anti-CD19/Anti-CD3/Anti-CD28 Trispecific Antibody CC312rule | cytocares-inc | phase 1 | 4 |
| Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565 | Novartis | phase 1 | 3 |
| ATG-201rule | antengene-biologics-limited | phase 1 | 1 |
| KT501rule | kali-therapeutics-inc | phase 1 | 1 |
| KT502rule | kali-therapeutics-inc | phase 1 | 1 |
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07917754Lymphoma, Large B-Cell, Diffuse | 3 | Not yet recruiting | Mar 13, 2037 | 470 |
| NCT07709000Leukemia, B-Cell · Colombia, Israel, Spain | 2 | Recruiting | Nov 16, 2033 | 60 |
| NCT07634471Lymphoma, Follicular · United States, Argentina, Australia and more | 3 | Recruiting | Jul 23, 2032 | 960 |
| NCT07570173Burkitt Lymphoma · Canada, Denmark, France and more | 3 | Recruiting | Oct 18, 2033 | 340 |
| NCT07519772Lymphoma, Non-Hodgkin · United States, Argentina, Australia and more | 2 | Recruiting | Jul 1, 2030 | 280 |
| NCT07363590Lupus Erythematosus, Systemic · Australia, Belgium, China and more | 1 | Recruiting | Jul 16, 2029 | 21 |
| NCT06189391Recurrence · China | 1 | Recruiting | Sep 30, 2028 | 100 |
| NCT05579132Precursor Cell Lymphoblastic Leukemia-Lymphoma · China | 2 | Recruiting | Dec 31, 2028 | 203 |
How it is read
Names in the registry
- “MK-1045”, 8 entries
Conditions, from the studies’ own filings
- Leukemia, Lymphocytic, Chronic, B-Cell, 1 study
- Lymphoma, Follicular, 1 study
- Lymphoma, Non-Hodgkin, 1 study
- Burkitt Lymphoma, 1 study
- Lymphoma, Large B-Cell, Diffuse, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.